Immunocore Ltd

Related records

Trials (20)

• A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp
• A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
• Adjuvant Tebentafusp in High Risk Ocular Melanoma
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
• IMCgp100-401 Rollover Study
• Neoadjuvant Tebentafusp for Uveal Melanoma
• Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
• Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
• Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
• Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
• Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
• Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
• Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
• Study of IMC-P115C in Advanced PRAME-Positive Cancers
• Study of IMC-S118AI in Type 1 Diabetes
• Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
• Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
• Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
• Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
• Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)